Alexza Pharmaceuticals, Inc. is a pharmaceutical company focused on the research, development and commercialization of products for the acute treatment of central nervous system conditions. The Company's product candidates are based on the Staccato system technology. Its product candidates in development include AZ-002, which contains alprazolam as an active pharmaceutical ingredient (API) is developed for the management of patients with acute repetitive seizures, and AZ-007, which contains zaleplon as API is developed for the treatment of insomnia in patients who have difficulty falling asleep, including those patients with middle of the night awakening having difficulty falling back asleep. Its product also includes ADASUVE, which contains loxapine as API is developed for the treatment of agitation associated with schizophrenia or bipolar disorder. It has initiated a Phase IIa proof-of-concept study for AZ-002 in patients with epilepsy and has completed Phase I testing for AZ-007.
Industry, Sector and Symbol
Industry N/A
Sub-IndustryN/A
SectorN/A
SymbolOTCMKTS:ALXA
CUSIPN/A
Phone+1-650-9447000
Debt
Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net Margins-466.94%
Return on EquityN/A
Return on Assets-106.54%
Miscellaneous
EmployeesN/A
Outstanding Shares21,750,000
Alexza Pharmaceuticals (OTCMKTS:ALXA) Frequently Asked Questions
What is Alexza Pharmaceuticals' stock symbol?
Alexza Pharmaceuticals trades on the OTCMKTS under the ticker symbol "ALXA."
How were Alexza Pharmaceuticals' earnings last quarter?
Alexza Pharmaceuticals, Inc. (OTCMKTS:ALXA) released its quarterly earnings data on Wednesday, May, 11th. The healthcare company reported ($0.16) EPS for the quarter. The healthcare company earned $0.72 million during the quarter. View Alexza Pharmaceuticals' Earnings History.
Has Alexza Pharmaceuticals been receiving favorable news coverage?
News headlines about ALXA stock have trended positive on Friday, according to Accern. Accern rates the sentiment of press coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Alexza Pharmaceuticals earned a media sentiment score of 0.31 on Accern's scale. They also gave news coverage about the healthcare company an impact score of 45.44 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company's share price in the next several days.
How do I buy shares of Alexza Pharmaceuticals?
Shares of ALXA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Alexza Pharmaceuticals' stock price today?
One share of ALXA stock can currently be purchased for approximately $0.9350.
How can I contact Alexza Pharmaceuticals?
Alexza Pharmaceuticals' mailing address is 2091 Stierlin Ct, MOUNTAIN VIEW, CA 94043-4655, United States. The healthcare company can be reached via phone at +1-650-9447000.
MarketBeat Community Rating for Alexza Pharmaceuticals (ALXA)
MarketBeat's community ratings are surveys of what our community members think about Alexza Pharmaceuticals and other stocks. Vote "Outperform" if you believe ALXA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ALXA will underperform the S&P 500 over the long term. You may vote once every thirty days.
